Standard Operating Procedure for Core Label Review and Market-Level Alignment
| Department | Regulatory Affairs |
| SOP No. | RA/2026/751 |
| Supersedes | NA |
| Page No. | 1 of X |
| Issue Date | 15/04/2026 |
| Effective Date | 15/04/2026 |
| Review Date | 15/04/2028 |
Purpose
This Standard Operating Procedure (SOP) establishes the standardized process for the comprehensive review of core product labels and their alignment with market-specific requirements. It ensures regulatory compliance, accuracy, and consistency across all labelling materials prior to product registration and distribution. This SOP supports the control objective of maintaining high-quality labelling documentation to meet both internal quality standards and global regulatory expectations.
Scope
This SOP applies to all core label development, review, and finalization processes related to pharmaceutical products within the Regulatory Affairs department. It encompasses review activities for labelling text, artwork, safety information, and regulatory claims for all dosage forms and markets globally. This SOP excludes finished product packaging operations and post-approval label change implementation processes managed by other departments.
Responsibilities
The following functional roles are involved:
- Regulatory Affairs Labeling Specialist – initiates core label drafts and coordinates reviews.
- Medical Affairs – reviews safety and clinical content for accuracy.
- Quality Assurance – oversees adherence to regulatory requirements and procedural compliance.
- Marketing – ensures alignment with brand strategy and market needs.
- Regulatory Affairs Manager – supervises the process and approves final label versions.
Accountability
The Regulatory Affairs Manager holds overall accountability for implementation, compliance, timely review, escalation of issues, and periodic evaluation of the effectiveness of this SOP.
Procedure
1. Preparation and Prerequisites: Regulatory Affairs Labeling Specialist obtains the latest approved core label template, relevant regulatory guidelines, and market-specific requirements. Verify all source documents and clinical data to support label claims.
2. Drafting Core Label: Develop the initial core label text and layout according to approved templates and regulatory standards, ensuring inclusion of all mandatory statements such as indications, dosage, warnings, and storage.
3. Internal Review: Circulate the draft label to involved departments, including Medical Affairs for safety verification, Quality Assurance for compliance checks, and Marketing for alignment with branding. Collect and compile feedback within the defined review period.
4. Revisions and Approvals: Regulatory Affairs Labeling Specialist incorporates all relevant comments, updating the label accordingly. Re-circulate updated drafts if necessary. Obtain formal approvals from Medical Affairs, Quality Assurance, and Regulatory Affairs Manager prior to finalization.
5. Market-Level Alignment: Align the finalized core label with specific market regulations and language requirements through cross-functional collaboration with local regulatory representatives. Ensure accurate translation and adaptation without compromising content integrity.
6. Documentation and Record Keeping: Archive all versions of the label drafts, review comments, approvals, and final label documents as per document control procedures. Maintain traceability for audits and regulatory inspections.
7. Deviations and Non-Conformance: Identify and document any deviations from the approved process or content standards. Issue a deviation report and follow corrective and preventive actions as defined by Quality Assurance.
8. Training and Communication: Provide relevant training to involved personnel on this SOP and any updates. Communicate finalized label versions to downstream functions responsible for implementation.
This procedure ensures that core labels are accurate, compliant, and properly aligned with market-specific requirements through a systematic, controlled review and approval process.
Abbreviations
RA – Regulatory Affairs
QA – Quality Assurance
MA – Medical Affairs
SOP – Standard Operating Procedure
GMP – Good Manufacturing Practices
Documents
- Core Label Review Checklist (Annexure-1)
- Label Change Approval Form (Annexure-2)
- Market Alignment Feedback Log (Annexure-3)
References
International Council for Harmonisation (ICH) Guidelines, Local Regulatory Authority Labeling Requirements, Internal Document Control Policies, Good Manufacturing Practices (GMP) for Labelling, Pharmacopoeial Standards for Product Information.
Version
1.0
Approval
| Prepared By | |
| Checked By | |
| Approved By |
Annexures
Annexure-1: Core Label Review Checklist
Purpose: To provide a comprehensive checklist for systematic review of core label elements ensuring regulatory compliance and content accuracy.
| Review Item | Status (Yes/No) | Comments |
|---|---|---|
| Indications and Usage Correct | Yes | N/A |
| Dosage Instructions Clear and Compliant | Yes | N/A |
| Warnings and Precautions Included | Yes | Reviewed by Medical Affairs |
| Storage Conditions Specified | Yes | N/A |
| Regulatory Statements Compliant | Yes | Confirmed by QA |
| Reviewed By | |
| Date | 10/04/2026 |
| Signature |
Annexure-2: Label Change Approval Form
Purpose: To document the approval of label changes after review and to ensure all stakeholders consent to the finalized label version.
| Label Change Reference Number | LBL-2026-042 |
| Description of Change | Updated dosage instructions for new formulation |
| Date Submitted for Approval | 12/04/2026 |
| Approving Department | Regulatory Affairs |
| Approval Status | Approved |
| Approver’s Signature | |
| Date of Approval | 14/04/2026 |
Annexure-3: Market Alignment Feedback Log
Purpose: To record feedback from market-specific stakeholders related to label adaptation and final alignment.
| Date | Market/Region | Feedback Provided | Action Taken | Status |
|---|---|---|---|---|
| 13/04/2026 | EU | Request to clarify excipient information | Updated excipient section as per guidance | Closed |
| 14/04/2026 | Japan | Translation accuracy concerns | Performed re-translation and review | Closed |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
| 15/04/2026 | 1.0 | Initial issue | New SOP creation |